Immunomodulation using placental stem cells

• US 8,895,256 B2
• Filed: 05/17/2012
• Issued: 11/25/2014
• Est. Priority Date: 10/13/2005
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Paludan, Casper, Edinger, James, Harbacheuski, Ryhor, Murray, RoseAnn, Hariri, Robert J.
• Primary Examiner(s): BELYAVSKYI, MICHAIL A
• Application Number:
  US13/474,378
• Publication Number:
  US 20120225096A1
• Time in Patent Office: 922 Days
• Field of Search: None
• US Class Current: 435/7.21
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2502/11 blood or immune system cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.

Claims

1. A method of suppressing or reducing a disease-associated immune response in a subject comprising administering a therapeutically effective amount of placental stem cells to the subject, wherein said placental stem cells suppress T cell proliferation stimulated by Epstein-Barr virus antigen-presenting B cells;

and

wherein at least 80% of said placental stem cells express CD200.

2. The method of claim 1, wherein said disease is multiple sclerosis, diabetes, lupus erythematosus, or rheumatoid arthritis.

3. The method of claim 2, wherein said therapeutically effective amount is an amount sufficient to improve one or more symptoms of multiple sclerosis, diabetes, lupus erythematosus, or rheumatoid arthritis in the subject.

4. The method of claim 1, comprising administering 1 million to 10 billion placental stem cells to said subject.

5. The method of claim 1, comprising administering 1 million to 100 million placental stem cells to said subject.

6. The method of claim 1, comprising administering 1×

10⁵ to 1×

10⁶ placental stem cells to said subject.

7. The method of claim 1, comprising administering 1×

10⁶ to 1×

10⁷ placental stem cells to said subject.

8. The method of claim 1, comprising administering 1×

10⁷ to 1×

10⁸ placental stem cells.

9. The method of claim 1, comprising administering 1×

10⁵ placental stem cells.

10. The method of claim 1, comprising administering 1×

10⁶ placental stem cells.

11. The method of claim 1, comprising administering 1×

10⁷ placental stem cells.

12. The method of claim 1, comprising administering 1×

10⁸ placental stem cells.

13. The method of claim 1, wherein said at least 80% of said placental stem cells are OCT-4⁺.

14. The method of claim 1, wherein said at least 80% of said placental stem cells are one or more of CD34⁻

, CD38⁻

, or CD45⁻

.

15. The method of claim 13, wherein said at least 80% of said placental stem cells are one or more of CD34⁻

, CD38⁻

, or CD45⁻

.

16. The method of claim 1, wherein said at least 80% of said placental stem cells are CD73⁺ or CD105⁺.

17. The method of claim 13 wherein said at least 80% of said placental stem cells are CD73⁺ or CD105⁺.

18. The method of claim 1, wherein said at least 80% of said placental stem cells are CD10⁺, CD34⁻

, CD105⁺ and CD200⁺.

19. The method of claim 1, wherein said placental stem cells are administered intravenously.

20. The method of claim 1, wherein said placental stem cells are administered directly into an organ.

21. The method of claim 1, wherein said placental stem cells are substantially non-maternal in origin.